EVOLV-Rx: Automated Decision Support for Eliminating Low-Value Clinical Practices

EVOLV-Rx is an automated data processing system that identifies low-value prescribing practices by extracting and analyzing subject data from multiple sources with varying data formats. The platform enables large-scale, automated detection of unnecessary or potentially harmful clinical practices, allowing healthcare entities to prioritize interventions and reduce adverse patient events.

Description

The technology functions by retrieving a plurality of data records for a subject from diverse sources, such as administrative claims data, electronic medical records (EMR) and pharmacy dispensing data. It identifies specific identifiers for medical conditions and assigned processes (e.g., medications) alongside a broad range of subject-specific properties like age, comorbidities, and laboratory values. The system then evaluates these parameters against multi-tiered, entity-specific criteria to detect "events", instances where a treatment may be ineffective, inappropriate, or dangerous for a specific patient cohort. A key innovation of the system is its ability to be operationalized for use using data from various sources with different formats, making it highly scalable for large datasets in hospitals or insurance companies. Once an event is detected, the system generates a notification to modify or terminate the low-value process, such as flagging the inappropriate use of inhaled corticosteroids in patients with mild COPD.

Applications

- Health Insurance & Payers: Automated auditing of claims data to identify and reduce reimbursement for low-value prescribing practices.
- Hospital Systems (EMR Integration): Real-time clinical decision support tools integrated into electronic medical records to alert providers to inappropriate treatments.
- Pharmacy Benefit Management (PBM): Monitoring pharmacy dispensing events to detect polypharmacy risks and drug-drug interactions in older adult populations.
- Chronic Disease Management: Specialized modules for managing high-risk treatments for conditions like COPD, Type II Diabetes, and dementia.
- Population Health Analytics: Large-scale cohort analysis for healthcare organizations to identify trends in low-value care and improve overall quality metrics.

Advantages

- Enhanced Patient Safety: Reduces the risk of adverse events and harm by flagging potentially dangerous or unnecessary medication uses.
- Operational Efficiency: Automates the detection of low-value care across large subject cohorts, saving time and resources compared to manual reviews.
- Resource Optimization: Identifies unnecessary consumption of medications and healthcare resources, allowing for more strategic clinical interventions.
- High Scalability: Designed to process large datasets from various data sources, organizations, and insurance companies regardless of internal data formats.
- Customizable Decision Logic: Allows different entities to implement their own specific policies and clinical criteria for event detection.

Invention Readiness

The technology has a well-defined system architecture and established clinical criteria for several major conditions, including COPD, Type II Diabetes, and dementia. It includes a "parameter extractor" and "event detector" capable of handling multi-format data records. Data has been generated regarding specific clinical algorithms, such as identifying low-value inhaled corticosteroid use in subjects over 65 based on their exacerbation history. Further studies are needed to integrate the tool into live clinical workflows and to expand the library of "low-value" criteria sets for additional therapeutic areas.

IP Status

Patent Pending

Quick Facts:
Reference Number
07182
Technology Type
Digital Health
Technology Subtype
Healthcare Data
Therapeutic Areas
Endocrinology and Metabolic DiseasesRespiratory
Therapeutic Indications
DiabetesChronic Obstructive Pulmonary Disease (COPD)
Tags
AgingAlgorithmPersonalized Medicine
Lead Inventor
Thomas Radomski
Department
Med-Medicine
All Tech Innovators
Thomas R. Radomski
Technology Readiness Level
4. Prototype testing and refinement
Date Submitted
2025-05-12
Collections
Cardiometabolic